China Eye Health Supplements Market Size & Outlook, 2025-2033

China Eye Health Supplements Market Insights

As highlighted in Deep Market Insights analysis, the China Eye Health Supplements Market, worth USD 138.99 Million in 2024, is forecasted to achieve USD 270.63 Million by 2033.
The China market is anticipated to grow at a CAGR of 7.74% during the period 2026–2033.
By 2024, Lutein And Zeaxanthin represented the largest share of the Ingredient Type market size.
Herbal Extracts is expected to remain the key growth driver within Ingredient Type, registering the fastest CAGR during the forecast period.

In 2024, China accounted for 6.62% of the global Eye Health Supplements Market size.
By 2033, United States is expected to lead the global Eye Health Supplements Market in terms of market size.
Within Asia Pacific, China is projected to dominate the regional Eye Health Supplements Market size by 2033.
India is identified as the fastest-growing market in Asia Pacific, anticipated to reach USD 128.57 Million by 2033.

Report Scope	Details
Base Year for Study	2024
Study Period	2021-2033
Historical Period	2021-2023
Forecast Period	2025-2033
Market Size In 2024	USD 138.99 Million
Market Size In 2033	USD 270.63 Million
Largest segment	Lutein And Zeaxanthin
Units	Revenue in USD Million
CAGR	7.74% (2025-2033)
Segmnetation Covered
Ingredient Type	Lutein And Zeaxanthin Omega Three Fatty Acids Antioxidant Compounds Herbal Extracts
Application	Age Related Macular Degeneration Cataract Prevention Dry Eye Syndrome General Vision Wellness
Dosage Form	Capsules And Softgels Tablets Liquid Supplements Powdered Formulations
Distribution Channel	Pharmacies And Drug Stores Online Retail Platforms Health And Wellness Stores Direct To Consumer Channels
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Ingredient Type	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033
Lutein And Zeaxanthin	XX.x	XX.x	XX.x	56.72	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Omega Three Fatty Acids	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Antioxidant Compounds	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Herbal Extracts	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

Application	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033
Age Related Macular Degeneration	XX.x	XX.x	XX.x	57.19	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Cataract Prevention	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Dry Eye Syndrome	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
General Vision Wellness	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

Dosage Form	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033
Capsules And Softgels	XX.x	XX.x	XX.x	57.81	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Tablets	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Liquid Supplements	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Powdered Formulations	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

Distribution Channel	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033
Pharmacies And Drug Stores	XX.x	XX.x	XX.x	56.75	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Online Retail Platforms	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Health And Wellness Stores	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Direct To Consumer Channels	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x